Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30464079 | 1.00 | TAAR1 (0.60) | TAAR1IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL4181180 | 0.86 | TAAR1 (0.56) | TAAR1IDO1CYP2D6CYP2C9LIPG | |
| SCHEMBL14302122 | 0.84 | LIPG (0.55) | TAAR1IDO1LIPGPPARGPPARA | |
| SCHEMBL27997934 | 0.84 | TAAR1 (0.71) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL551121 | 0.82 | LIPG (0.58) | TAAR1LIPGPPARGPPARA | |
| SCHEMBL8766368 | 0.82 | LIPG (0.58) | TAAR1LIPGPPARGPPARA | |
| SCHEMBL3899345 | 0.82 | LIPG (0.58) | TAAR1LIPGPPARGPPARA | |
| SCHEMBL29554553 | 0.82 | LIPG (0.58) | TAAR1LIPGPPARGPPARA | |
| SCHEMBL5599179 | 0.82 | LIPG (0.58) | TAAR1LIPGPPARGPPARA | |
| SCHEMBL29488434 | 0.81 | ADRA2B (0.44) | TAAR1ADRA2AADRA2BADRA2CLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074305-A1 | TETRAHYDRONAPHTHALENE-BASED ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE | SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-114394923-B | Preparation method of N-acyl-2-alkyl indoline compound | 浙江工业大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117500785-A | Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115044508-B | Lactococcus lactis subspecies lactis and application thereof in three-bean soup fermented beverage | 锦州医科大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-114394923-A | Preparation method of N-acyl-2-alkyl indoline compound | 浙江工业大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-109021022-B | Luminescent diazabenzimidazole carbene metal complexes | UDC 爱尔兰有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | BRITISH COLUMBIA CANCER AGENCY BRANCH | 2021-01-05 | — | — | US | disclosed |
| US-10765681-B2 | Purine compounds possessing anticancer activity | ACADEMIA SINICA (TW) | 2020-09-08 | — | — | US | disclosed |
| EP-3353167-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-06-24 | — | — | EP | disclosed |
| EP-3521272-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | Ozchela Inc. (KR) | 2019-08-07 | — | — | EP | disclosed |
| EP-1707263-B1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | TOSOH CORP (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| CN-1409699-A | Process for preparation of secondary and tertiary amines | CELGRO (US) | 2003-04-09 | — | — | CN | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-6080870-A | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| EP-0891333-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036875-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | KLK3, FOLH1, FOLR1 | TAAR1 2458/4885IDO1 4110/4885ADRA2A 3880/4885 |
| US-10765681-B2 | Purine compounds possessing anticancer activity | NTPCR, PNP, NUDT1 | TAAR1 3117/4885IDO1 1499/4885ADRA2A 2982/4885 |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | TAAR1 108/4885IDO1 642/4885ADRA2A 2385/4885 |
| US-20240074305-A1 | TETRAHYDRONAPHTHALENE-BASED ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE | EXOC1, TRPA1, CYBA | TAAR1 2082/4885IDO1 1663/4885ADRA2A 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.